ArticleAlcohol, clinical & experimental research2025
Patient perspectives on medications for alcohol use disorder: A systematic scoping review.
Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Discontinuation of medications for alcohol use disorder in the United States: Patient, prescriber and medication predictors.Addiction (Abingdon, England) · 2026Observational
- Optimizing outpatient pharmacologic treatment for veterans with alcohol use disorder using an academic detailing approach for primary care providers in the United States Department of Veterans Affairs: A retrospective quasi-experimental study.Addiction (Abingdon, England) · 2026Article
- Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease.Alimentary pharmacology & therapeutics · 2025Article
- Patient perspectives on medications for alcohol use disorder: A systematic scoping review.Alcohol, clinical & experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Front-line treatments for alcohol use disorder (AUD) include psychotherapy and medication, and both treatments are underused. However, utilization rates of medications for alcohol use disorder (MAUD) are particularly low. The goal of the present scoping review is to characterize patient perspectives about MAUD to identify barriers to MAUD and potential areas of future work to increase access, initiation, and retention on MAUD. Searches of titles and abstracts were conducted on PubMed, EMBASE, PsycINFO, and CINAHL until March 2024 with patient perspective-, MAUD-, and alcohol-related keywords. Articles were assessed for eligibility and included in the present review if they examined adult patients' perspectives of MAUD. Fourteen studies were included in the review. The majority of patient populations assessed were individuals with AUD, and most studies evaluated MAUD in general (n = 7) or specific medications (i.e., naltrexone, n = 5; disulfiram, n = 2; acamprosate, n = 1). Important themes related to patient-perceived barriers to MAUD were identified, including a lack of awareness and misunderstanding about the effectiveness and effects of MAUD, apprehensiveness or experience with side effects, and perceived stigma of MAUD. Future work incorporating patient perspectives of MAUD into interventions and strategies may help improve MAUD uptake, including person-centered discussions factoring in unique patient perspectives about MAUD to increase patient MAUD knowledge and reduce MAUD stigma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.